News Focus
News Focus
Replies to #64409 on Biotech Values
icon url

DewDiligence

07/18/08 7:50 AM

#64411 RE: DewDiligence #64409

Teva-Barr addendum: Inasmuch as BRL was emerging as a serious contender in the FoB arena (based on its 2007 acquisition of Pliva), the TEVA-BRL deal reduces the number of FoB players by one.